Cargill, Evolva to develop steviol glycosides

THE newly forged partnership between Evolva Holding SA and Cargill enables the first-ever venture into fermentation-based steviol glycosides. Cargill, which will provide expertise in manufacturing and commercialisation, agrees to make a US$5.3 million equity investment in its new partner.  Evolva will receive $7.5 million in milestone payments and has the right to a 45% participation in the final business. Should it decide not to exercise this option, it will receive royalty payments from global sales of the co-developed steviol glycoside products; these royalties will scale from mid-single digit to low double-digit percentages as a function of sales volume and other parameters.